Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Clinical trial NCT06921785 · RECRUITING

Trial details

NCT number: NCT06921785
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2025-05-06
Primary completion: 2029-03-16
Enrollment: 1220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.